Trials / Completed
CompletedNCT05728528
Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
Impact of Moderate to Vigorous-intensity Physical Activities on Pharmacokinetic-guided Extended Half-life FVIII Concentrates Prophylaxis Severe Hemophilia A Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To compare clinical outcomes before and after using combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis in moderate to severe hemophilia A patients
Detailed description
This is a prospective cohort study of severe hemophilia A patients receiving low-dose EHL FVIII concentrates with PK-guided EHL FVIII concentrates prophylaxis alone for 6 months. Additional exercise workshops from sport scientists were introduced individually to this group of patients along with using the same prophylaxis method for another period of 6 months. The annualized bleeding rates (ABR), the annualized joint bleeding rates (AJBR), the haemophilia-specific quality-of-life (Haemo-QoL-A) scores, the hemophilia Joint Health Scores (HJHS) and skeletal muscle mass were compared between these two periods
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis | combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis |
| DRUG | pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone | pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2023-02-15
- Last updated
- 2023-02-15
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT05728528. Inclusion in this directory is not an endorsement.